Phillipe Dro joins NeMoDevices

The ETH spin-off NeMoDevices has introduced Phillipe Dro as the new CEO. Philippe Dro previously served as CEO of GlycoVaxyn AG, a Swiss biotech startup in vaccines, which was acquired by GSK in early 2015. Before GlycoVaxyn, he was CEO of EndoArt SA, a medtech spin-off from the École polytechnique fédérale de Lausanne (EPFL), which was acquired by Allergan in early 2007. With his experience, he will assist NeMoDevises bring innovation to new heights.

“Having worked with the Management Team and the Board of Directors for a while, I was impressed by the potential of the platform and the people behind it. The products from NeMoDevices are providing physicians key information on brain blood flow and oxygen levels that enable bridging the gap from merely monitoring to individualized patient treatment. I am thrilled to join this team and would like to thank Michael Oberle for his valuable contribution as CEO.” said Philippe Dro. Michael Oberle will continue to support the company as COO.

“We are delighted that he is joining the Management Team as CEO and look forward to benefit from his product development and commercialization experience to further accelerate the development of NeMoDevices.” said Emanuela Keller, founder and member of the Board of Directors of NeMoDevices.

About NeMoDevices
NeMoDevices AG is a medtech company specialising in the development of innovative solutions for the simultaneous monitoring of critical brain oxygenation and circulation parameters. The company has applied its proprietary platform based on Near-InfraRed Spectroscopy (NIRS) technology in two products: the minimally invasive NeMo Probe and the non-invasive NeMo Patch. The NeMo Probe received CE Mark approval in 2015. CE Mark approval for NeMo Patch is anticipated in 2017. The company is currently investigating the US regulatory pathway to obtain US marketing approval for both NeMo Probe and NeMo Patch.